Hsp90 Inhibitors Current Events | Hsp90 Inhibitors News
|
| Page
1 of
16 |
311 Results |
|
|
|
Sort By:
Page Views | Date |
The Hsp90-Antifungal Combo, please: Compromising fungi in the immunocompromised
Even the most drug-resistant fungi can be eradicated in multiple in vitro and in vivo models using a lethal combination of an antifungal agent and inhibition of the heat shock protein Hsp90, according to a new study by Whitehead Institute and University of Toronto researchers. view more (2009-02-10)
First high-res 3D structures of mammalian HSP90 protein solved
Dr. Dan Gewirth, Hauptman-Woodward senior research scientist, has just solved the structure of the first mammalian GRP94 protein implicated in immune diseases such as sepsis, AIDS and certain cancers. view more (2007-10-15)
Sidestepping cancer's chaperone
Cancerous tumors are wildly unfavorable environments. Struggling for oxygen and nutrients while being bombarded by the body's defense systems, tumor cells in fact require sophisticated adaptations to survive and grow. view more (2007-10-22)
Targeting helpers of heat shock proteins could help treat cancer, cardiovascular disease
Dissecting how heat shock protein 90 gets steroid receptors into shape to use hormones like estrogen and testosterone could lead to targeted therapies for hormone-driven cancers, such as breast and prostate, that need them as well, Medical College of Georgia researchers say. view more (2009-06-23)
Chemical genomic screening identifies novel therapeutic strategies for cancer
A sophisticated new chemical genetic screening strategy that serves as a tool for identifying anticancer compounds may significantly enhance the drug discovery process. view more (2006-09-29)
Researchers find docking sites for glucocorticoid receptor and Hsp90
University of Oregon researchers have identified protein interactions that regulate the response of cells to steroid hormones. The discovery, they say, could lead to new ways to boost the effectiveness and reduce undesired side effects of steroid-hormone treatments and cancer drugs. view more (2006-11-21)
Investigational cancer drug targets critical proteins
A drug under study to treat various cancers selectively kills cancer cells because of its affinity for a modified version of a critical heat shock protein they contain, researchers have found. view more (2007-04-16)
HSP90: New point of view on melanoma of the eye, at the MUHC
Ocular melanoma is rarely detected before it has grown large enough to impair vision or to metastasize. This makes it a particularly challenging disease to fight, especially since chemotherapy is not very effective. view more (2008-02-20)
Researchers aim to over-stress already taxed mantle cell lymphoma cells
Cancer cells are already stressed by the fast pace they require to grow and spread and scientists believe a little more stress just may kill them. view more (2008-11-11)
New cancer target for non-Hodgkin's lymphoma
Physician-scientists from Weill Cornell Medical College have discovered a molecular mechanism that may prove to be a powerful target for the treatment of non-Hodgkin's lymphoma, a type of cancer that affects lymphocytes, or white blood cells. view more (2009-11-23)
A chemotherapy drug packs a one-two punch
Cancer can be wily, and those who treat the disease have amassed a wide array of weapons with which to fight it and kill tumors. view more (2007-02-21)
Regular use of selective COX-2 inhibitors decreases risk of breast cancer
Regular use of selective COX-2 inhibitors significantly reduces the risk of breast cancer. view more (2006-01-30)
Aromatase inhibitors: A treatment of choice for advanced breast cancer patients
Aromatase inhibitors improve the survival of advanced breast cancer patients compared to standard hormone therapies like tamoxifen. view more (2006-09-20)
New arthritis drugs less likely to cause side effects
A new group of arthritis drugs recommended by NICE for patients at risk of gastrointestinal complications may be safer than traditional drugs, research in this week's BMJ suggests. Claims that the drugs, known as selective COX2 inhibitors, caused fewer gastrointestinal problems than traditional arthritis drugs led to an increase in their use, but... view more... (2002-09-18)
Aspirin Does Not Reduce Effectiveness Of ACE Inhibitors
A systematic review in this week's issue of THE LANCET provides clarification for the debate about the use of angiotensin-converting-enzyme (ACE) inhibitors in combination with aspirin for the treatment of cardiovascular disease-combination therapy does not reduce the effect of ACE inhibition. Previous research has suggested that ACE inhibitors... view more... (2002-10-02)
Drugs may not delay onset of dementia; and more
Researchers have examined the evidence in favour of giving people considered to be close to developing dementia the drugs that are most commonly used to treat the condition itself. view more (2007-11-27)
Combination therapy reduces tumor resistance to radiation
Radiation is used to treat a variety of tumors and the response of tumors to radiation is dependent on endothelial cell death, which in turn limits oxygen delivery to the tumor, causing hypoxia and tumor cell death. view more (2007-06-08)
Experiments point to new treatments for PKD
A family of small molecules called CFTR inhibitors show promising effects in slowing the progression of polycystic kidney disease (PKD), the most common genetic disease of the kidneys, according to preliminary research reported in the July 2008 issue of the Journal of the American Society Nephrology. view more (2008-04-03)
Safety claims of new arthritis drugs may be misleading
Popular arthritis drugs, known as selective COX 2 inhibitors, may not be superior to traditional non-steroidal anti-inflammatory drugs, conclude researchers in this week’s BMJ. view more (2002-05-28)
A new approach to study flu drug resistance
Researchers have created a new approach for studying resistance to Neuraminidase Inhibitors (NI) in influenza. view more (2007-12-07)
|
|
| Page
1 of
16 |
311 Results |
|
|
|
Sort By:
Page Views | Date |
|
